Sector ratings Novo Nordisk A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 19:20:00 04/06/2026 +04			5-day change	1st Jan Change
283.85 ^DKK	+4.43%		-3.11%	-12.73%

06-06	Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits	RE
06-06	Novo Nordisk Reports Real-World Evidence Comparing Semaglutide 2 Mg Dose Escalation Versus Switch to Tirzepatide in Adults with Type 2 Diabetes	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
NOVO NORDISK A/S	194B		A
ELI LILLY AND COMPANY	1,009B		A
JOHNSON & JOHNSON	560B		BBB
ABBVIE INC.	401B	-	AA	-	-
ROCHE HOLDING AG	328B		AA
ASTRAZENECA PLC	288B		A
NOVARTIS AG	272B		AAA
AMGEN INC.	189B		A
GILEAD SCIENCES, INC.	160B		AA
PFIZER INC.	148B		A
BRISTOL-MYERS SQUIBB COMPANY	117B		A
VERTEX PHARMACEUTICALS INCORPORATED	113B		AA
SANOFI	108B		AA
GSK PLC	103B		AA
CHUGAI PHARMACEUTICAL CO., LTD.	77.57B		AA
TAKEDA PHARMACEUTICAL COMPANY LIMITED	48.56B		AA
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	46.02B		AA
BAYER AG	41.02B		AA
ALNYLAM PHARMACEUTICALS, INC.	40.46B		AA
TEVA PHARMACEUTICAL INDUSTRIES LIMITED	39.81B		-
Average	214.26B		AA
Weighted average by Cap.			AA